Regulators Confirm Benefits of AstraZeneca Vaccine Outweigh Risks

News
Article

MHRA and EMA have confirmed that the benefits of the AstraZeneca COVID-19 vaccine continue to outweigh the risk of side effects.

The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom and the European Medicines Agency (EMA) have confirmed that the benefits of the AstraZeneca COVID-19 vaccine continue to outweigh the risk of side effects.

After a scientific review, MHRA concluded that there was no evidence of blood clots in veins occurring more than would be expected in the absence of vaccination. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has also concluded that there is no increased overall risk of blood clots with the AstraZeneca COVID-19 vaccine. A causal link between thromboembolic events and the vaccine has not been established and is not proven.

In a March 18, 2021 press release, AstraZeneca confirmed that it will continue to work closely with regulators to ensure the COVID-19 vaccine is used appropriately and will implement the recommendations of PRAC, which include updated product information. Additionally, the company has stated it will continue to work on the understanding behind the nature and relevance of the thromboembolic events to ensure the safe delivery of the vaccine continues.

“Vaccine safety is paramount and we welcome the regulators’ decisions which affirm the overwhelming benefit of our vaccine in stopping the pandemic,” said Ann Taylor, chief medical officer, in the press release. “We trust that, after the regulators’ careful decisions, vaccinations can once again resume across Europe.”

Source: AstraZeneca

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes